Latest News - Baxter
Top Corporates Hub
Baxter
Baxter (NYSE:BAX) Reports Sales Below Analyst Estimates In Q3 Earnings, Stock Drops 13.5%
30.10.2025 12:44
Healthcare company Baxter International (NYSE:BAX) missed Wall Street’s revenue expectations in Q3 CY2025, but sales rose 5% year on year to $2.84 billion. Next quarter’s revenue guidance of $2.81 billion underwhelmed, coming in 6.5% below analysts’ estimates. Its non-GAAP profit of $0.69 per share was 15.4% above analysts’ consensus estimates.
Baxter International (BAX) Beats Q3 Earnings Estimates
30.10.2025 12:25
Baxter (BAX) delivered earnings and revenue surprises of +15.00% and -1.32%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Baxter International Inc. 2025 Q3 - Results - Earnings Call Presentation
30.10.2025 11:38
2025-10-30. The following slide deck was published by Baxter International Inc.
Baxter International Inc. (BAX) Q3 2025 Earnings Call Transcript
30.10.2025 11:26
Baxter International Inc. (BAX) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDTCompany ParticipantsKevin MoranAndrew Hider - CEO, President &...
Baxter: Q3 Earnings Snapshot
30.10.2025 11:23
The Deerfield, Illinois-based company said it had a loss of 9 cents per share. Earnings, adjusted for one-time gains and costs, were 69 cents per share. The results topped Wall Street expectations.
Baxter Reports Third-Quarter 2025 Results
30.10.2025 11:15
DEERFIELD, Ill., October 30, 2025--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the third quarter of 2025.
Healthcare Industry Resilience Collaborative (HIRC) Awards Gold Level Resiliency Badge to Baxter International Inc. (BAX)
02.10.2025 00:09
With significant upside potential, Baxter International Inc. (NYSE:BAX), secures a spot on our list of the 12 Best Widow and Orphan Stocks to Buy According to Analysts. On September 26, 2025, Baxter International Inc. (NYSE:BAX), a leading global medtech company, was awarded a Gold Level Resiliency Badge by the Healthcare Industry Resilience Collaborative (HIRC) across […]
3 Reasons to Avoid BAX and 1 Stock to Buy Instead
24.09.2025 04:04
Baxter has gotten torched over the last six months - since March 2025, its stock price has dropped 32% to $22.86 per share. This was partly driven by its softer quarterly results and might have investors contemplating their next move.
Baxter launches Welch Allyn Connex 360 Vital Signs Monitor
17.09.2025 11:17
The device enables care teams to obtain patient vitals in under one minute and automatically sends data to electronic medical record.
Medical Affairs Leader Dr. Kirk Shepard Joins BP Logix’s Life Sciences Strategic Advisory Board
26.08.2025 11:00
SAN DIEGO, August 26, 2025--As part of its mission to drive innovation in Medical Affairs automation, BP Logix is pleased to announce the appointment of Dr. Kirk Shepard to the company's Life Sciences Strategic Advisory Board.
Sigmoidoscopes Market Insights, Competitive Landscape, and Forecast 2022-2024 & 2025-2032 | North America, Healthcare Advancements and Geriatric Populations Drive Growth
08.08.2025 11:13
The sigmoidoscopes market, segmented by product type, usability, end-user, and geography, is forecasted to grow at a 5.57% CAGR from 2025 to 2032. This growth is driven by rising chronic conditions, a growing geriatric population, and increased awareness about early diagnosis of gastrointestinal disorders globally. North America is expected to dominate the market, aided by technological innovations and healthcare investments. Key players include Olympus Corporation, Baxter, and Johnson & Johnson
Baxter International Inc. (BAX): A Bull Case Theory
06.08.2025 02:37
We came across a bullish thesis on Baxter International Inc. on DeepValue Capital’s Substack. In this article, we will summarize the bulls’ thesis on BAX. Baxter International Inc.’s share was trading at $22.44 as of August 4th. BAX’s trailing and forward P/E were 84.46 and 8.71, respectively according to Yahoo Finance. Baxter International (BAX), a nearly century-old […]
Stifel downgrades Baxter as it sees longer path to recovery under new CEO
04.08.2025 14:09
Investing.com -- Stifel downgraded Baxter International (NYSE:BAX) to Hold from Buy and slashed its price target to $25 from $36, citing a weaker-than-expected second quarter and a longer timeline for operational turnaround under incoming CEO Andrew Hider.
Baxter’s shares fall 23% following tepid Q2 2025 financials
04.08.2025 12:19
The Q2 results, that missed analyst estimates, also led to a trimming of Baxter’s 2025 outlook.
Are Wall Street Analysts Bullish on Baxter International Stock?
04.08.2025 11:10
While Baxter International has lagged the broader market over the past year, Wall Street analysts remain cautiously optimistic about its future potential.
Europe Syringe Infusion Pump Market Analysis Report 2025-2030, with Key Player Profiles for B. Braun, Baxter, Fresenius Kabi, Micrel Medical Devices, CODAN, Acromed, ICU Medical, Terumo, and Moog
04.08.2025 08:08
The European Syringe Infusion Pump Market, valued at USD 465.1M in 2024, is projected to reach USD 729.5M by 2030, growing at a 7.90% CAGR. This growth is driven by rising preterm births, chronic diseases, and advanced technology adoption. Leading segments include pediatrics/neonatology and hospitals. Germany holds the largest market share, with rapid growth expected in home care. The report offers detailed market analysis, future trends, and actionable recommendations for strategic decision-mak
Blood Purification Devices Market Competitive Landscape, and Market Forecasts to 2032
01.08.2025 14:12
The Blood Purification Devices Market is expected to grow at a 5.40% CAGR, reaching USD 26.86 billion by 2032. Growth factors include rising kidney disease cases, hypertension, and diabetes. Key segments are CRRT devices, with North America leading. Major players include Fresenius, B. Braun, and Baxter.Dublin, Aug. 01, 2025 (GLOBE NEWSWIRE) -- The "Blood Purification Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032" has been added to ResearchAndMarkets.com's offering.
Avis Budget downgraded, Sprouts upgraded: Wall Street's top analyst calls
01.08.2025 13:34
Avis Budget downgraded, Sprouts upgraded: Wall Street's top analyst calls
InMode (INMD) Q2 Earnings and Revenues Beat Estimates
30.07.2025 12:10
InMode (INMD) delivered earnings and revenue surprises of +9.30% and +0.11%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?